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Abstracts / Osteoarthritis and Cartilage 20 (2012) S10–S53 S31time course of the experiment (ADAMTS5 and MMP13 were not regu-
lated at day 14), whilst the heterodimer had little effect. Interestingly,
S100A9 induced greater gene expression changes than S100A8 at days 1
and 2, whilst at later time points, S100A8 induced greater changes.
While there were some temporal differences, IL-1a and the S100
monomers upregulated mRNA expression of a similar spectrum of
MMPs and ADAMTSs. There were also no signiﬁcant differences in gene
expression between IL-1a treated explants with or without addition of
the S100s. Strikingly, despite the pro-catabolic gene expression changes
induced by stimulation with S100A8 or S100A9, this did not translate
into increased pro or active MMP-2, -9 or-13, nor did it lead to an
increase in aggrecan or collagen release at any time compared with
control cultures. In contrast, IL-1a stimulated increased aggrecan
release and active MMP-13 in media from day 2 onwards, as well as
active MMP-2 from day 4.
Conclusions: Taken together this data suggests that S100A8 and
S100A9 may prime the cartilage for degradation through the upregu-
lation of pro-enzymes, however a second co-factor appears to be
needed in order to activate the system and induce actual cartilage
degradation. The requirement for a co-stimulatory factor(s) is remi-
niscent of the need for both inﬂammasome assembly to activate cas-
pase-1, in concert with the effect of pro-inﬂammatory stimuli (TLR
activation or IL-1a/TNF), in order to get secretion of active IL-1b in the
innate immune response. S100A8 and S100A9 are re cognised both as
ligands for TLRs; and as damage associated molecular patterns
(DAMPs), many of which can activate the inﬂammasome/caspase1.
However, expression of TLR2/4 by chondrocytes is low in normal
cartilage and upregulated in OA and/or by inﬂammatory cytokines. We
could not demonstrate synergism between IL-1a and S100s; however
this may reﬂect an already maximal response with the dose of IL-1a
used in the present study. Ongoing studies will determine if sub-
maximal doses of IL-1a or TNFa can enhance the chondrolytic activity of
S100s through upregulation of TLRs.
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CONNECTIVE TISSUE GROWTH FACTOR/CCN FAMILY 2 IS
A PERICELLULAR PROTEIN WHOSE CELLULAR RESPONSE IS
DEPENDENT UPON THE TGFb TYPE I RECEPTOR
X. Tang, C. McLean, T. Vincent. Imperial Coll. London, London, United
kingdom.
Purpose: Previous work from our lab and others has identiﬁed an
important role for the pericellular matrix (PCM) of cartilage in
sequestering regulatory cartilage molecules such as FGF2 (Vincent et al.
2002; Vincent et al. 2007). A proteomic analysis of PCM proteins carried
out in our lab has identiﬁed, amongst other things, connective tissue
growth factor (CTGF). CTGF is a member of the CCN family and is
regarded as a ‘matricellular’ protein though how it exerts its cellular
effects are unknown. It has been suggested to act both as a cofactor for
TGFb family members (Abreu et al. 2002) as well as being a bridging
molecule between the cell surface and the extracellular matrix (Chen et
al. 2004). CTGF is essential for musculoskeletal development; knockout
mice die early after birth due to impaired development of cartilage and
bone (Ivkovic et al 2003). We have observed that CTGF is constitutively
expressed in porcine and normal human articular cartilage and is
increased in osteoarthritis (OA) (Hermansson et al. 2004). Although
there are reports that CTGF regulates matrix synthesis, little is known
about its role in articular cartilage.
Methods: The localization of CTGF in articular cartilage was deter-
mined by confocal microscopy. His-tagged human recombinant CTGF
protein was stably expressed in HEK293 cells and puriﬁed using nickel
afﬁnity chromatography. Cells (human dermal ﬁbroblast or human
articular chondrocytes) were stimulated with puriﬁed CTGF for
candidate gene expression analysis (type II collagen, type X collagen,
ﬁbronectin and perlecan). Endogenous CTGF was inhibited by siRNA
mediated knock down. To look for novel gene targets a microarray
study was performed on siRNA transfected (scrambled or CTGF)
human chondrocytes with or without CTGF stimulation. Target genes
were validated by quantitative real time PCR (Q-PCR). Their depen-
dence on TGFb family signaling was demonstrated using the TGFb type
I receptor SB431542.
Results: CTGF co-localised with perlecan in the PCM of human articular
cartilage and was increased in OA tissue. Stimulation of cells with CTGF
did not increase mRNA levels for a range of matrix proteins, nor were
these affected when endogenous CTGF was knocked down by siRNA. A
microarray analysis identiﬁed three strongly regulated genes: bonemorphogenetic protein receptor type II (BMPR2), transmembrane
prostate androgen-induced protein (TMEPAI or PMEPA1) and latent
TGF-beta binding protein 2 (LTBP2). These were validated using Q-PCR
and showed an early and transient response to CTGF stimulation. All
three genes are known to be TGFb dependent suggesting that CTGFmay
be exerting its effect through TGFb-type signalling. To test this we
stimulated cells with CTGF in the presence of SB431542. This abrogated
the gene responses.
Conclusions: We have identiﬁed three novel gene targets of CTGF in
human articular chondrocytes and human dermal ﬁbroblasts. The
induction of these genes is dependent upon TGFb receptor signaling.
There has been much debate as to how such matricellular proteins
affect cellular responses. Our data support one published theory that
CTGF is able to modulate TGFb family responses (Abreu et al 2002). The
mechanism by which this occurs is being explored.
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DEVELOPMENT OF PAIN AND FUNCTION IN 3 YEARS OF FOLLOW-UP;
COMPARISON BETWEEN CHECK STUDY (COHORT HIP & COHORT
KNEE) AND OSTEOARTHRITIS INITIATIVE
J. Wesseling 1, S.M. Bierma-Zeinstra 2, G. Kloppenburg 3, J.W. Bijlsma 1. on
behalf of the CHECK steering group1Univ. Med. Ctr. Utrecht, Utrecht,
Netherlands; 2 Erasmus Med. Ctr., Rotterdam, Netherlands; 3 Leiden Univ.
Med. Ctr., Leiden, Netherlands
Purpose: Pain and disability related to osteoarthritis (OA) may
generally be considered to be chronic, but it is known that its course
can be very different between patients. In this study, it is investi-
gated whether there is a difference in development of pain and
physical functioning during follow-up between two OA cohorts,
Osteoarthritis Initiative (OAI) and Cohort Hip & Cohort knee study
(CHECK).
Methods: For the current study, longitudinal data of three years
follow-up of the CHECK study and OA Initiative were used. The
CHECK study is a Dutch prospective 10-year follow-up study, initi-
ated by the Dutch Arthritis Association, to study progression of OA in
participants with early symptomatic OA of knee or hip. Individuals
were eligible if they had pain of knee or hip, were aged 45-65 years,
and had not yet consulted their physician for these symptoms. In the
same time in the U.S. an observational 4-year follow-up study was
started to create a public archive of data, biological samples and joint
images to study the natural history of, and risk factors for, the onset
and progression of knee OA. In both cohorts the WOMAC was
utilized to measure pain during activities (range 0-20) and physical
functioning (range 0-68). For comparison with CHECK a subgroup of
the incidence OAI cohort was selected which was comparable with
the CHECK cohort: participants with age 45-65 years, frequent or
infrequent knee symptoms and no surgery in either knee. General-
ized estimating equations (GEE) were used to account for correla-
tions within individuals and the effect modiﬁer (OAcohort* time)
was also investigated within the model.
Results: For this study, the data of 688 CHECK participants with knee
pain at baseline were analyzed; mean age 56 years, BMI 25 kg/m2 and
80% female. The subgroup of OAI incidence cohort with infrequent or
frequent knee pain consisted of 1417 participants, with a mean age of
56, BMI of 28 and 64% female. The CHECK cohort reported at baseline
more pain and more problems in physical functioning compared to the
subgroup of OAI incidence cohort (p< 0.000). A ﬁnal longitudinal
regression model with pain as outcome and adjusted for BMI shows
that pain is 3 points lower (better health) of participants in the
subgroup of OAI incidence cohort, and improves in both cohorts after 1
year of follow-up with 0.2 points, after 2 years with 0.3 points, after 3
years with 0.3 points. In a ﬁnal model with function as outcome and
adjusted for BMI, this outcome is 10.2 points higher (worse health) in
CHECK cohort and improves in both cohorts after 1 year of follow-up
with 0.6 points, after 2 years with 0.8, and after 3 years with 0.7 points.
These results were not inﬂuenced by the characteristics of both cohorts
(effect modiﬁer (OAcohort* time) was not statistically signiﬁcant in
both outcomes).
Conclusions: In the total group of the OAI incidence-subgroup and
CHECK participants with knee pain there is a gradually improvement
over 3 years time in pain and physical functioning, despite different
baseline values on pain and physical functioning. In the early phase
of knee OA there is overall a gradually improvement in the com-
plaints.
